Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Intermediate release Paliperidone · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Intermediate release (IR) Paliperidone | DRUG | - |
Inclusion Criteria: * Patients with normal hepatic function:Normotensive at screening, with supine (5 minutes) blood pressure between the range of 95 to 160 mmHg systolic, inclusive, and 55 to 95 mmHg diastolic, inclusive, demographically comparable to the hepatic impairment group with respect to a...
Intermediate release Paliperidone is an investigational small molecule being studied for the treatment of schizophrenia. It is in Phase 1 clinical development. The drug is being evaluated in a pharmacokinetic study involving volunteers with normal or impaired liver function, with the condition of schizophrenia listed as a study condition.
Intermediate release Paliperidone is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The drug is currently in Phase 1 clinical development for the treatment of schizophrenia.
Intermediate release Paliperidone is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 clinical trial has been completed, and the drug remains in early-stage clinical development for schizophrenia.
Intermediate release Paliperidone has one completed clinical trial, identified as NCT00791284. This Phase 1 study, titled 'A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver Function,' enrolled 20 participants and included healthy volunteers. The study was uncontrolled and not randomized or double-blinded.
Intermediate release Paliperidone is a formulation of paliperidone, an antipsychotic medication. The drug is being developed by Johnson & Johnson for schizophrenia. The clinical trial NCT00791284 specifically studies the pharmacokinetics of paliperidone in volunteers with normal or impaired liver function.